Lyell Immunopharma Inc (LYEL) is around the top of the Biotechnology industry according to InvestorsObserver. LYEL received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Lyell Immunopharma Inc also achieved a score of 74 in the Biotechnology industry, putting it above 74 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.
LYEL has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on LYEL!
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With Lyell Immunopharma Inc Stock Today?
Lyell Immunopharma Inc (LYEL) stock is lower by -6.49% while the S&P 500 has gained 0.46% as of 2:47 PM on Tuesday, Mar 19. LYEL has fallen -$0.13 from the previous closing price of $2.08 on volume of 1,627,845 shares. Over the past year the S&P 500 has gained 30.91% while LYEL has fallen -10.14%. LYEL lost -$0.93 per share the over the last 12 months.
Click Here to get the full Stock Report for Lyell Immunopharma Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
